Claims
- 1. A pharmaceutical composition for treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism comprising a lipoteichoic acid and a pharmaceutically acceptable carrier.
- 2. The pharmaceutical composition of claim 1, wherein the lipoteichoic acid is from at least one gram-positive organism.
- 3. The pharmaceutical composition of claim 1, wherein the gram-positive organism belongs to Streptococcus, Micrococcus, Lactobacillus, Staphylococcus, Bacillus, or Listeria.
- 4. The pharmaceutical composition of claim 1, wherein the gram-positive organism is S. aureus, S. epidermidis, S. pyogenes, N. cereus, or L. monocytogenes.
- 5. The pharmaceutical composition of claim 1, wherein the gram-positive organism belongs to Streptococcus group A, B, C, or G.
- 6. The pharmaceutical composition of claim 1, wherein the gram-positive organism belongs to group A Streptococcus.
- 7. A pharmaceutical composition for treating, preventing, or inhibiting a infection or disease caused by a gram-positive organism comprising an antibody which specifically binds to a lipoteichoic acid and a pharmaceutically acceptable carrier.
- 8. The pharmaceutical composition of claim 7, wherein the lipoteichoic acid is from at least one gram-positive organism.
- 9. A vaccine for providing protection against an infection or a disease caused by a gram-positive organism comprising a lipoteichoic acid or an immunogenic composition comprising lipoteichoic acid.
- 10. The vaccine of claim 9, wherein the lipoteichoic acid is from at least one gram-positive organism.
- 11. The vaccine of claim 10, wherein the gram-positive organism belongs to Streptococcus, Micrococcus, Lactobacillus, Staphylococcus, Bacillus, or Listeria.
- 12. The vaccine of claim 11, wherein the gram-positive organism is S. aureus, S. epidermidis, S. pyogenes, N. cereus, or L. monocytogenes.
- 13. The vaccine of claim 12, wherein the gram-positive organism belongs to Streptococcus group A, B, C, or G.
- 14. The vaccine of claim 12, wherein the gram-positive organism belongs to group A Streptococcus.
- 15. The vaccine of claim 9, further comprising a suitable adjuvant.
- 16. A method of treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 1.
- 17. A method of treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism in a subject comprising administering to the subject a therapeutically effective amount of a vaccine according to claim 7.
- 18. A method of treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism in a subject comprising administering to the subject a therapeutically effective amount of a vaccine according to claim 9.
- 19. A method of immunizing a subject against an infection or disease caused by a gram-positive organism comprising administering to the subject an immunogenic amount of lipoteichoic acid.
- 20. The method of claim 19, wherein the immunogenic amount is an amount that induces protective anti-adherence, opsonophagocytic antibodies against a gram-positive organism, or both in the subject.
- 21. The method of claim 19, wherein the subject is a mammal.
- 22. The method of claim 21, wherein the mammal is human.
- 23. A kit for treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism in a subject comprising a composition a therapeutically effective amount of a lipoteichoic acid.
- 24. The kit of claim 23, wherein the therapeutically effective amount is an amount that induces protective anti-adherence, opsonophagocytic antibodies against a gram-positive organism in the subject, or both.
- 25. The kit of claim 23, further comprising a device for administering the composition, directions for use, reagents for detecting or measuring the protective anti-adherence, opsonophagocytic antibodies, or both in the subject, or a combination thereof.
- 26. A kit for treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism in a subject comprising a composition comprising at least one antibody which specifically binds to a lipoteichoic acid.
- 27. The kit of claim 26, further comprising directions for use, reagents for detecting or measuring the amount of gram-positive organisms in the subject, or both.
- 28. The method of claim 19, wherein the infection or disease is septicemia, septic shock, toxic shock syndrome, multiple organ failure, an infection due to a medical device, osteomyelitis, cellulitis, pharyngitis, a wound infection, pneumonia, gastroenteritis, conjunctivitis, endocarditis, myositis, necrotizing fasciitis, bronchitis, septic arthritis, septic bursitis, neonatal sepsis, bacteremia, an abscess, suppurative phlebitis, sialoadenitis, dental caries, meningitis, or sinusitis.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/231,959, filed Sep. 12, 2000, naming Joseph J. Drabick and David L. Hoover as co-inventors, which is herein incorporated by reference.
ACKNOWLEDGMENT OF GOVERNMENT INTEREST
[0002] This invention was made by employees of the United States Army. The government has rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60231959 |
Sep 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09948553 |
Sep 2001 |
US |
Child |
10370596 |
Feb 2003 |
US |